Organization and Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023	Sep. 30, 2024	Jun. 30, 2024	Sep. 30, 2023	Jun. 30, 2023
Product Information [Line Items]
Net loss	$ 299,000	$ 14,000	$ 525,000	$ 264,000
Accumulated deficit	23,000	1,186,000	23,000	1,186,000	$ 707,000	$ 480,000	$ 1,170,000	$ 919,000
[custom:ProceedsFromPatentAssignment]			880,000	0
Cash and Cash Equivalents, at Carrying Value	681,000		681,000			179,000
Cash equivalents	0		0			0
Cash uninsured amount	431,000		431,000
Write-down of investment	1,000		1,000			1,000
Research and development expense	16,000	$ 0	24,000	$ 36,000
Receivables from customers	$ 0		$ 0			$ 0
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Desmet [Member]
Product Information [Line Items]
Concentration risk, percentage			100.00%	100.00%
Accounts Payable [Member] | Customer Concentration Risk [Member] | Vendor One [Member]
Product Information [Line Items]
Concentration risk, percentage			19.00%	19.00%
Accounts Payable [Member] | Customer Concentration Risk [Member] | Vendor Two [Member]
Product Information [Line Items]
Concentration risk, percentage			13.00%	15.00%
Accounts Payable [Member] | Customer Concentration Risk [Member] | Vendor Three [Member]
Product Information [Line Items]
Concentration risk, percentage			11.00%	11.00%
Patent Transfer To Desmet [Member]
Product Information [Line Items]
[custom:ProceedsFromPatentAssignment]			$ 880,000